ABPI appoints new president

Deepak Khanna takes over from Simon Jose

Deepak Khanna, senior vice president and MSD UK managing director, has been appointed as president of the Association of the British Pharmaceutical Industry (ABPI) after his recent election. He takes over from Simon Jose of GSK, and will serve for one year with the option of standing for re-election in a year’s time.

Commenting on the appointment, Stephen Whitehead, ceo of the ABPI, said: ‘We are entering a new era of working in partnership with the NHS and Deepak’s leadership in these early stages will be crucial as we imbed new ways of working that will further patient care in the UK. The pricing of medicines and the negotiations we are entering in to later this year will be crucial to the future success of our industry and I know that Deepak’s wealth of experience will be invaluable.’

You may also like

Drug Delivery

ABPI: “New antibiotics key against resistance infections”

In 2019, it was estimated that 1.2 million deaths globally, were due to antibiotic-resistant infections
Regulatory

ABPI: Tackling vaccine hesitancy should be a priority

The Association of the British Pharmaceutical Industry responds to the UK's commitment to improving declining vaccination rates
Regulatory

New medicine safety initiative goes live across the UK and Europe

The ABPI raises concerns about the safety of the UK's medicines in a ‘no deal’ Brexit
Research & Development

ABPI urges the UK to address the skills shortage in STEM

Highly skilled scientific roles could move elsewhere if the situation is not addressed as a matter of urgency
Regulatory

Waiting in the shadow of a no deal Brexit

Pharmaceutical companies still do not know how they will be impacted by Brexit after Prime Minister Theresa May decided to postpone a vote on her deal with the European Union (EU), writes Paul Brooks, Executive Director, RAPS
Regulatory

NHS, Pharma and Biotech industries call on Government to protect patients in future UK-EU relationship

A coalition from the UK’s health sector say Brexit negotiators have a responsibility to protect 500 million patients on both sides of the Channel. The group is calling on both sides to make patients and public health central to the Political Declaration for the future relationship between the UK and the EU
Research & Development

Scotland’s manufacturing exports worth £462 million

The Scottish pharmaceutical industry is ‘booming’ and is now the second biggest spender on R&D, a new report has revealed
Subscribe now